A Phase 1 interventional study of LY3537982 and Digoxin in Healthy, sponsored by Eli Lilly and Company. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-11-08.
Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The main purpose of this study is to evaluate the effects of multiple doses of LY3537982 on the pharmacokinetics (PK) of digoxin (a P-glycoprotein [P-gp] substrate), rosuvastatin (a breast cancer resistance protein [BCRP)] substrate), and midazolam (a substrate of Cytochrome P450 3A4 [CYP3A4]) in adult healthy participants. The study will also evaluate the safety and tolerability of LY3537982 with or without single doses of digoxin, rosuvastatin, and midazolam. The study is conducted in two parts. Participants will stay in the research center during the study, which will last about 23 and 11 days for part 1 and part 2, respectively, not including screening.
Eli Lilly and Company is the lead sponsor of 2,109 studies on the registry; 153 are open to participants now.
Of its 540 completed or terminated interventional studies of FDA-regulated products, 358 (66%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Single oral doses of digoxin and rosuvastatin with or without multiple doses of LY3537982 administered orally
Drug: LY3537982 · Drug: Digoxin · Drug: Rosuvastatin
Single doses of midazolam administered either orally or intravenously (IV) with or without multiple doses of LY3537982 administered orally
Drug: LY3537982 · Drug: Midazolam
Administered orally
Also known as: Olomorasib
Administered orally
Administered orally
Administered orally
Administered IV
Part 1: Pharmacokinetics (PK): Maximum Observed Concentration (Cmax) of LY3537982
Part 1: PK: Cmax of LY3537982
Time frame: Predose on day 11 up to day 17
Part 1: PK: Area Under the Concentration-Time Curve (AUC) from Time 0 to Infinity (AUC[0-inf]) of LY3537982
Part 1: PK: AUC\[0-inf\] of LY3537982
Time frame: Predose on day 11 up to day 17
Part 1: PK: AUC from Time 0 to time of the last measurable concentration (AUClast) of LY3537982
Part 1: PK: AUClast of LY3537982
Time frame: Predose on day 11 up to day 17
Part 1: PK: Cmax of Digoxin
Part 1: PK: Cmax of Digoxin
Time frame: Predose on day 1 up to day 21
Part 1: PK: AUC[0-inf] of Digoxin
Part 1: PK: AUC\[0-inf\] of Digoxin
Time frame: Predose on day 1 up to day 21
Part 1: PK: AUClast of Digoxin
Part 1: PK: AUClast of Digoxin
Time frame: Predose on day 1 up to day 21
Part 1: PK: Cmax of Rosuvastatin
Part 1: PK: Cmax of Rosuvastatin
Time frame: Predose on day 1 up to day 21
Part 1: PK: AUC[0-inf] of Rosuvastatin
Part 1: PK: AUC\[0-inf\] of Rosuvastatin
Time frame: Predose on day 1 up to day 21
Part 1: PK: AUClast of Rosuvastatin
Part 1: PK: AUClast of Rosuvastatin
Time frame: Predose on day 1 up to day 21
Part 2: PK: Cmax of LY3537982
Part 2: PK: Cmax of LY3537982
Time frame: Predose on day 4 up to day 11
Part 2: PK: AUC[0-inf] of LY3537982
Part 2: PK: AUC\[0-inf\] of LY3537982
Time frame: Predose on day 4 up to day 11
Part 2: PK: AUClast of LY3537982
Part 2: PK: AUClast of LY3537982
Time frame: Predose on day 4 up to day 11
Part 2: PK: Cmax of Midazolam
Part 2: PK: Cmax of Midazolam
Time frame: Predose on day 1 up to day 9
Part 2: PK: AUC[0-inf] of Midazolam
Part 2: PK: AUC\[0-inf\] of Midazolam
Time frame: Predose on day 1 up to day 9
Part 2: PK: AUClast of Midazolam
Part 2: PK: AUClast of Midazolam
Time frame: Predose on day 1 up to day 9
Part 2: PK: Cmax of 1'-Hydroxymidazolam
Part 2: PK: Cmax of 1'-Hydroxymidazolam
Time frame: Predose on day 1 up to day 9
Part 2: PK: AUC[0-inf] of 1'-Hydroxymidazolam
Part 2: PK: AUC\[0-inf\] of 1'-Hydroxymidazolam
Time frame: Predose on day 1 up to day 9
Part 2: PK: AUClast of 1'-Hydroxymidazolam
Part 2: PK: AUClast of 1'-Hydroxymidazolam
Time frame: Predose on day 1 up to day 9
Plan to share: No
No publications or documents are linked to this record.
Ran from Oct 2023 to primary completion in Apr 2024, 5 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Olomorasib